secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECIGEN, INC. (PGEN)
CIK:        0001356090
Form:       8-K
Filed at:   2026-03-25T23:59:59+00:00
Accession:  0000950103-26-004648
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precigen posts FY2025 net loss of $1.37/sh; PAPZIMEOS Q4 revenue $3.4M, launch momentum strong
--------------------------------------------------------------------------------

- PAPZIMEOS generated $3.4M in net product revenue in Q4 2025, first partial quarter of US commercial sales.
- Cash, cash equivalents, and investments $100.4M as of Dec 31, 2025, expected to fund to cash flow break-even.
- Patient hub enrollment >300; payer coverage ~215M lives (~90% insured US); CMS assigned permanent J-code effective Apr 1, 2026.
- Net loss attributable to common shareholders $429.6M ($1.37/sh) vs $126.2M ($0.47) in 2024, driven by non-cash warrant and preferred stock items.
- R&D expenses down 22.1% YoY; SG&A up 69.8% reflecting commercial launch investment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356090/000095010326004648/0000950103-26-004648-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356090/000095010326004648/dp244075_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-26-004648

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer